The landscape of respiratory virus protection is poised for a significant shift as Moderna prepares to launch the first combined influenza and COVID-19 vaccine in Europe in 2026. This development arrives after a period of uncertainty for the biotech firm, marked by regulatory hurdles and legal challenges, but recent progress suggests a positive turning point for the company and the future of preventative medicine. The anticipated vaccine represents a streamlined approach to annual immunization, potentially increasing uptake and offering broader protection against two major public health threats.
Earlier this year, Moderna faced setbacks. In early February, the U.S. Food and Drug Administration (FDA) initially declined to review the data for its mRNA-1010 vaccine, designed to combat seasonal influenza. Simultaneously, the company found itself embroiled in patent infringement lawsuits filed by BioNTech, a German biotechnology company. Despite these challenges, Moderna’s stock has surged, increasing by 83% since January, though it remains 85% below its peak valuation during the height of the COVID-19 pandemic in 2021.
FDA Reversal and Promising Trial Data
A key factor in Moderna’s recent gains is the FDA’s reversal regarding the mRNA-1010 vaccine. The agency has now agreed to review the application for approval, with a decision expected by August 5th. The initial indication is for individuals aged 50 and older, with a potential accelerated review pathway for those 64 and above. This decision follows a Phase 3 trial involving over 40,000 participants, which demonstrated a favorable benefit-risk profile for the vaccine. The trial results are crucial as they provide evidence of the vaccine’s efficacy and safety, paving the way for potential authorization.
The development of a combined influenza and COVID-19 vaccine is a significant step forward in preventative healthcare. Currently, individuals typically receive separate vaccinations for each virus, which can lead to lower compliance rates. A single, combined vaccine could simplify the immunization process and improve overall protection, particularly for vulnerable populations. This approach aligns with public health goals of increasing vaccination coverage and reducing the burden of respiratory illnesses.
European Launch and Market Potential
While the FDA review is ongoing in the United States, Moderna is prioritizing a 2026 launch of the combined vaccine in Europe. This strategic move allows the company to capitalize on the anticipated demand for a more convenient immunization option. The European market represents a substantial opportunity for Moderna, given the region’s robust healthcare infrastructure and commitment to public health initiatives. The company is actively working with European regulatory authorities to secure approval and prepare for widespread distribution.
The potential impact of this vaccine extends beyond individual health benefits. By reducing the incidence of both influenza and COVID-19, the combined vaccine could alleviate strain on healthcare systems, decrease hospitalizations, and minimize economic disruptions caused by widespread illness. This is particularly relevant given the ongoing evolution of both viruses and the potential for future outbreaks.
BioNTech Lawsuits and Patent Disputes
Despite the positive developments surrounding the mRNA-1010 vaccine, Moderna continues to navigate legal challenges from BioNTech. The German company alleges that Moderna’s vaccines infringe on its patents related to mRNA technology. These lawsuits could potentially impact Moderna’s ability to market and sell its vaccines, and the outcome of these legal battles remains uncertain. Fierce Pharma provides further coverage of the legal disputes.
Current COVID-19 Vaccine Landscape
As of March 5, 2026, the FDA has revoked the Emergency Use Authorization (EUA) for the original Moderna COVID-19 Vaccine. However, Spikevax (COVID-19 Vaccine, mRNA), manufactured for Moderna US Inc., remains fully approved for use. The FDA has authorized updated, bivalent mRNA COVID-19 vaccines for all doses for individuals ages 6 months and older. Fact sheets for recipients, caregivers, and healthcare providers are available as of June 25, 2025.
The shift towards fully approved vaccines and the development of combination vaccines reflect a maturing phase in the response to COVID-19. While the virus continues to circulate, the availability of effective vaccines and treatments has significantly reduced the severity of illness and the risk of hospitalization. The focus is now on integrating COVID-19 vaccination into routine immunization schedules and developing strategies to address emerging variants.
Looking ahead, the FDA’s decision on the mRNA-1010 vaccine will be a critical milestone for Moderna. A positive outcome would not only validate the company’s research and development efforts but as well pave the way for a broader rollout of the combined influenza and COVID-19 vaccine in Europe and potentially other regions. The success of this vaccine could reshape the landscape of respiratory virus prevention and contribute to a healthier future.
This is a developing story. We will continue to provide updates as more information becomes available. Share your thoughts on the potential impact of a combined flu and COVID-19 vaccine in the comments below.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
